Address: 1 Broadway, Cambridge, MA02142 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
Date: 3.31-4.1 2023
Location: King of Prussia, Pennsylvania
Date: April 25-26, 2023
Location: Etc. venues 155 Bishopsgate, London
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Our Biology Department boasts a variety of technical solutions, professional scientific research teams, various advanced biological instruments and biological laboratories. Medicilon has rich experience in biological fields such as molecular biology, cell biology, in vitro biology, structural biology, among others.
With our technical platforms such as enzyme level and cell level measurement platforms, we help our clients select compounds and research their properties, action mechanism and bio-marker analysis, thus ensuring the effective implementation of our clients' projects and helping promote the process of drug R&D.
PROTAC (proteolysis-targeting chimera) is a bifunctional specific small molecule. It can be understood as a dumbbell-shaped chimera, of which one end is used to target the target protein to be degraded, the other end is used to recruit protein degradation systems like E3 ubiquitin ligase and both ends are connected by a suitable linker. Therefore, the chimera is a ternary chimera featuring target protein - PROTAC - E3 ubiquitin ligase that promises close connection between target protein and E3 ligase, so that the target protein can be ubiquitinated and then further recognized and degraded by proteasome.
In theory, this new mechanism can target all drug target proteins, especially those that are previously thought to be undruggable, thus expanding the field of drug research and promising incalculable space and application prospects for new drugs R&D. PROTAC technology is novel and has many advantages compared with traditional micromolecule drugs, antibody drugs, RNAi, etc.. It is considered as one of the popularities in the field of drug R&D.
As we know, a complete monoclonal antibody includes an antigen-binding fragment (Fab) and a fragment crystallizable region (Fc). The Fab can bind to a tumor-associated antigen, while the Fc plays an important role in metabolic pathways, as well as in IgG cellular functions.
The molecular sequence and subtype of antibodies will affect the effector functions. Such effector functions include the antibody dependent cellular cytotoxicity (ADCC) triggered by Fc binding to the FcγRIII receptor (CD16A) of NK. The Fc can also bind with serum complement molecules (C1q) to form a membrane attack complex (MAC) that triggers complement-dependent cytotoxicity (CDC). When the Fc binds with macrophage receptors—namely FcγRIII (CD16A), FcγRII (CD32A) and FcγRI (CD64)—the antibody-dependent cellular phagocytosis (ADCP) is triggered.
ABOUT
